Table 2 Change in best corrected visual acuity (BCVA) according to different baseline characteristics
Change in BCVA from baseline to month 6c, n (%) | |||||
|---|---|---|---|---|---|
≥ 5 | ≥ 10 | ≥ 15 | ≤5 | pa | |
Diagnosis | |||||
CRVO | 5 (19.2) | 5 (20.8) | 5 (25.0) | 9 (42.9) | 0.0728b |
BRVO | 21 (80.8) | 19 (79.2) | 15 (75.0) | 12 (57.1) | |
Treatment status | |||||
Naïve | 18 (69.2) | 18 (75.0) | 14 (70.0) | 9 (42.9) | 0.0690b |
Previously treated | 8 (30.8) | 6 (25.0) | 6 (30.0) | 12 (57.1) | |
ME durationd | |||||
≤ 32 days | 10 (38.5) | 9 (37.5) | 9 (45.0) | 13 (61.9) | 0.1010b |
> 32 days | 16 (61.5) | 15 (62.5) | 11 (55.0) | 8 (38.1) | |
Type of RVO-ME | |||||
SLRS | 0 (0.0) | 0 (0.0) | 0 (0.0) | 2 (9.5) | 0.1877 |
CME | 8 (30.8) | 7 (29.4) | 8 (40.0) | 9 (42.9) | |
SRD | 18 (69.2) | 17 (70.8) | 12 (60.0) | 10 (47.6) | |
HRF, n (%) | |||||
< 10 | 5 (19.2) | 4 (16.7) | 5 (25.0) | 6 (28.6) | 0.7126 |
10–20 | 14 (53.8) | 13 (54.2) | 7 (35.0) | 7 (33.3) | |
> 20 | 7 (26.9) | 7 (29.2) | 8 (40.0) | 8 (38.1) | |
ELM, n (%) | |||||
Non-disrupted | 6 (23.1) | 6 (25.0) | 3 (15.0) | 4 (19.0) | 0.3960 |
Partially disrupted | 15 (57.7) | 13 (54.2) | 10 (50.0) | 7 (33.3) | |
Disrupted | 5 (19.2) | 5 (20.8) | 7 (35.0) | 10 (47.6) | |
DRIL, n (%) | |||||
No | 9 (34.6) | 8 (33.3) | 5 (25.0) | 11 (52.4) | 0.3391b |
Yes | 17 (65.4) | 16 (66.7) | 15 (75.0) | 10 (47.6) | |
Cysts, n (%)e | |||||
< 100 μm | 0 (0.0) | 0 (0.0) | 0 (0.0) | 2 (10.0) | 0.2014 |
100–200 μm | 7 (26.9) | 6 (25.0) | 3 (15.0) | 3 (15.0) | |
> 200 μm | 19 (73.1) | 18 (75.0) | 17 (5.5) | 15 (75.0) | |